MYC and cancer: Importantly, by specifically inhibiting the expression of NUDT1, we demonstrate synthetic lethality in MYC-overexpressing cells and dramatically decreased tumorigenic potential in vivo, illuminating an important vulnerability and therapeutic window for cancers driven by “undruggable” oncogenes, such as MYC.